The University of Michigan Health System in Ann Arbor and the International Genetics Consortium, based in Phoenix, have partnered to launch a non-profit joint venture to support genetic research and personalized medicine.
The joint venture, Paradigm, is being formed under the Michigan Health Corporation, an arm of UMHS that enables outside partnerships. Paradigm will offer whole gene and multi-gene sequencing and molecular diagnostics to providers across the country and will also help support various clinical trials.
"Pursuing new, innovative channels for scientific collaboration is a priority and strength of the University of Michigan," said Ora Pescovitz, MD, CEO of the U-M Health System and U-M executive vice president for medical affairs, in a statement. "Paradigm is a terrific example of this effort and of how cutting-edge science will have an immediate benefit for patients."
The joint venture, Paradigm, is being formed under the Michigan Health Corporation, an arm of UMHS that enables outside partnerships. Paradigm will offer whole gene and multi-gene sequencing and molecular diagnostics to providers across the country and will also help support various clinical trials.
"Pursuing new, innovative channels for scientific collaboration is a priority and strength of the University of Michigan," said Ora Pescovitz, MD, CEO of the U-M Health System and U-M executive vice president for medical affairs, in a statement. "Paradigm is a terrific example of this effort and of how cutting-edge science will have an immediate benefit for patients."
More Articles on University of Michigan Health System:
University of Michigan Health Launches New Oncology Research Program
University of Michigan Health Program Reduces Readmissions
University of Michigan Health Adds 14 Cardiologists to Meet Outpatient Demand